Medicare Enrolled
Dr. Deborah Fein, MD
Nephrology · Englewood, NJ
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Fein from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Fein?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Fein
Dr. Deborah Fein is a nephrology specialist in Englewood, NJ, with 20 years of NPI registration. Based on federal Medicare data, Dr. Fein performed 1,266 Medicare services across 818 unique beneficiaries.
Between the years covered by Open Payments, Dr. Fein received a total of $3,288 from 37 pharmaceutical and/or device companies across 181 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in nephrology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Fein is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ 1,266 Medicare services
$3,288 industry payments
Medicare Practice Summary
Medicare Utilization ↗1,266
Medicare services
Bottom 42% in NJ for nephrology
818
Unique beneficiaries
$124
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~63 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
334 | $97 | $240 |
| Dialysis services for patients 20 or older Dialysis treatment provided to patients aged 20 years or older, involving four or more physician visits per month. |
178 | $302 | $1,185 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
136 | $65 | $160 |
| Electrocardiogram (EKG), 12-lead A standard heart rhythm test using at least 12 leads to record electrical activity. A healthcare provider interprets the results and provides a written report. |
80 | $10 | $60 |
| Annual wellness visit, follow-up A follow-up annual wellness visit that includes a personalized prevention plan of service. |
76 | $146 | $395 |
| Dialysis services for adults, 2-3 visits per month This code covers dialysis services for patients aged 20 or older who have 2 to 3 physician visits per month. |
60 | $258 | $985 |
| Hemodialysis, single evaluation A dialysis procedure to filter waste from the blood, performed with a physician's evaluation. |
59 | $59 | $235 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
53 | $150 | $325 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
45 | $76 | $165 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
42 | $147 | $445 |
| Hospital follow-up visit, low complexity Follow-up hospital visit for an established patient with straightforward or low-level medical decision making. The visit requires at least 25 minutes of time spent on the day of service. |
38 | $41 | $85 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
28 | $104 | $230 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
24 | $5 | $5 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
23 | $32 | $70 |
| Flu vaccine, high-dose High-dose seasonal influenza vaccine for adults aged 65 and older. Contains four times the antigen of standard-dose flu vaccines (60 mcg per strain), split-virus formulation, preservative-free, single-dose syringe. |
22 | $69 | $90 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
22 | $103 | $300 |
| COVID-19 vaccine administration Administration of a single dose of the coronavirus vaccine. |
16 | $42 | $120 |
| COVID-19 vaccine (Pfizer bivalent) Administration of a 30 mcg dose of the SARS-CoV-2 vaccine via intramuscular injection. |
16 | $120 | $220 |
| Hemodialysis procedure requiring repeated evaluation A hemodialysis treatment that involves repeated evaluation during the procedure. |
14 | $89 | $340 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$3,288
Total received (2018-2024)
Avg $470/year across 7 years
Top 20% in NJ for nephrology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
181
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,199 (97.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$89 (2.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,286
2023
$759
2022
$60
2021
$19
2020
$68
2019
$641
2018
$455
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Ardelyx, Inc.
$217
AstraZeneca Pharmaceuticals LP
$166
Amgen Inc.
$162
CALLIDITAS THERAPEUTICS US INC.
$158
Novartis Pharmaceuticals Corporation
$123
Fresenius USA Marketing, Inc.
$107
Novo Nordisk Inc
$71
Travere Therapeutics, Inc.
$65
Aurinia Pharma U.S., Inc.
$47
Vifor Pharma, Inc.
$46
Bayer Healthcare Pharmaceuticals Inc.
$38
GlaxoSmithKline, LLC.
$33
OPKO Pharmaceuticals, LLC
$18
Otsuka America Pharmaceutical, Inc.
$18
PFIZER INC.
$17
Top 3 companies account for 42.4% of 2024 payments
All-time payments by company (2018-2024) ›
Amgen Inc.
$392
AstraZeneca Pharmaceuticals LP
$303
Ardelyx, Inc.
$217
Novartis Pharmaceuticals Corporation
$207
Fresenius USA Marketing, Inc.
$200
Bayer Healthcare Pharmaceuticals Inc.
$185
CALLIDITAS THERAPEUTICS US INC.
$158
Otsuka America Pharmaceutical, Inc.
$158
OPKO Pharmaceuticals, LLC
$142
BARD PERIPHERAL VASCULAR, INC.
$125
Janssen Pharmaceuticals, Inc
$119
Novo Nordisk Inc
$113
Vifor Pharma, Inc.
$108
AKEBIA THERAPEUTICS INC
$106
GlaxoSmithKline, LLC.
$98
Relypsa, Inc.
$98
Travere Therapeutics, Inc.
$65
Lilly USA, LLC
$53
Merck Sharp & Dohme Corporation
$52
Aurinia Pharma U.S., Inc.
$47
PFIZER INC.
$46
Bayer HealthCare Pharmaceuticals Inc.
$30
Calliditas Therapeutics US Inc.
$30
Horizon Therapeutics plc
$28
Shire North American Group Inc
$26
Regeneron Healthcare Solutions, Inc.
$19
ANI Pharmaceuticals, Inc.
$17
Keryx Biopharmaceuticals, Inc.
$17
Mallinckrodt LLC
$16
SANOFI PASTEUR INC.
$15
Xeris Pharmaceuticals, Inc.
$15
Strongbridge US INC.
$15
Alexion Pharmaceuticals, Inc.
$15
Mallinckrodt Enterprises LLC
$14
Otsuka Pharmaceutical Development & Commercialization, Inc.
$14
Genentech USA, Inc.
$14
ARBOR PHARMACEUTICALS, INC.
$12
Top 3 companies account for 27.7% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AFINITOR · AREXVY · AURYXIA · Aimovig · Aranesp · Auryxia · BENLYSTA · EMGALITY · EVENITY · EVKEEZA · Edarbi · FARXIGA · FLUZONE HIGH-DOSE · GATTEX · IBSRELA · INVOKANA · JANUVIA · JESDUVROQ · JYNARQUE · KEVEYIS · KRYSTEXXA · Kerendia · LOKELMA · LUPKYNIS · LYRICA · Levemir · MOUNJARO · NATPARA · Ozempic · PAXLOVID · PREVNAR - 13 · PURIFIED CORTROPHIN GEL · Parsabiv · RAYALDEE · Rayaldee · Repatha · Rituxan · Rybelsus · SHINGRIX · SOLIRIS · TARPEYO · TAVNEOS · Velphoro · Veltassa · Wegovy · XARELTO · XPHOZAH 30 MG
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (97%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Nephrologists within 10 mi
711
Per 100K population
74.5
County median income
$123,715
Nearest hospital
ENGLEWOOD HOSPITAL AND MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Fein is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement in the top 20% of NJ peers, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Fein experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Fein performed 334 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Fein receive payments from pharmaceutical companies?
Yes. Dr. Fein received a total of $3,288 from 37 companies across 181 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Fein's costs compare to other nephrologists in Englewood?
Dr. Fein's average Medicare payment per service is $124. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Fein) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Nephrology
Common procedures, typical costs, and what industry payments mean in nephrology.
Same specialty & city
Nephrologists in Englewood
Browse nephrologists in Englewood ranked by procedure volume and transparency data.
Highest volume
Top Nephrologists in NJ
Nephrologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Nephrologists in NJ
Which NJ nephrologists receive the most from drug and device companies.
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Ardelyx, Inc. Payments to Doctors
See all physicians who received payments from Ardelyx, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology